Cargando…

Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case

BACKGROUND: The use of cost-effectiveness thresholds based on a country’s income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer-Rath, Gesine, van Rensburg, Craig, Larson, Bruce, Jamieson, Lise, Rosen, Sydney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658054/
https://www.ncbi.nlm.nih.gov/pubmed/29073167
http://dx.doi.org/10.1371/journal.pone.0186496
_version_ 1783273923036577792
author Meyer-Rath, Gesine
van Rensburg, Craig
Larson, Bruce
Jamieson, Lise
Rosen, Sydney
author_facet Meyer-Rath, Gesine
van Rensburg, Craig
Larson, Bruce
Jamieson, Lise
Rosen, Sydney
author_sort Meyer-Rath, Gesine
collection PubMed
description BACKGROUND: The use of cost-effectiveness thresholds based on a country’s income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiveness threshold for HIV prevention and treatment interventions based on estimates of life years saved and the country’s committed HIV budget. METHODS: We analysed the optimal mix of HIV interventions over a baseline of the current HIV programme under the committed HIV budget for 2016–2018. We calculated the incremental cost-effectiveness ratio (ICER) as cost per life-year saved (LYS) of 16 HIV prevention and treatment interventions over 20 years (2016–2035). We iteratively evaluated the most cost effective option (defined by an intervention and its coverage) over a rolling baseline to which the more cost effective options had already been added, thereby allowing for diminishing marginal returns to interventions. We constrained the list of interventions to those whose combined cost was affordable under the current HIV budget. Costs are presented from the government perspective, unadjusted for inflation and undiscounted, in 2016 USD. RESULTS: The current HIV budget of about $1.6 billion per year was sufficient to pay for the expansion of condom availability, medical male circumcision, universal treatment, and infant testing at 6 weeks to maximum coverage levels, while also implementing a social and behavior change mass media campaign with a message geared at increasing testing uptake and reducing the number of sexual partners. The combined ICER of this package of services was $547/ LYS. The ICER of the next intervention that was above the affordability threshold was $872/LYS. CONCLUSIONS: The results of the South African HIV Investment Case point to an HIV cost-effectiveness threshold based on affordability under the current budget of $547–872 per life year saved, a small fraction of the country’s GDP per capita of about $6,000.
format Online
Article
Text
id pubmed-5658054
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56580542017-11-09 Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case Meyer-Rath, Gesine van Rensburg, Craig Larson, Bruce Jamieson, Lise Rosen, Sydney PLoS One Research Article BACKGROUND: The use of cost-effectiveness thresholds based on a country’s income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiveness threshold for HIV prevention and treatment interventions based on estimates of life years saved and the country’s committed HIV budget. METHODS: We analysed the optimal mix of HIV interventions over a baseline of the current HIV programme under the committed HIV budget for 2016–2018. We calculated the incremental cost-effectiveness ratio (ICER) as cost per life-year saved (LYS) of 16 HIV prevention and treatment interventions over 20 years (2016–2035). We iteratively evaluated the most cost effective option (defined by an intervention and its coverage) over a rolling baseline to which the more cost effective options had already been added, thereby allowing for diminishing marginal returns to interventions. We constrained the list of interventions to those whose combined cost was affordable under the current HIV budget. Costs are presented from the government perspective, unadjusted for inflation and undiscounted, in 2016 USD. RESULTS: The current HIV budget of about $1.6 billion per year was sufficient to pay for the expansion of condom availability, medical male circumcision, universal treatment, and infant testing at 6 weeks to maximum coverage levels, while also implementing a social and behavior change mass media campaign with a message geared at increasing testing uptake and reducing the number of sexual partners. The combined ICER of this package of services was $547/ LYS. The ICER of the next intervention that was above the affordability threshold was $872/LYS. CONCLUSIONS: The results of the South African HIV Investment Case point to an HIV cost-effectiveness threshold based on affordability under the current budget of $547–872 per life year saved, a small fraction of the country’s GDP per capita of about $6,000. Public Library of Science 2017-10-26 /pmc/articles/PMC5658054/ /pubmed/29073167 http://dx.doi.org/10.1371/journal.pone.0186496 Text en © 2017 Meyer-Rath et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Meyer-Rath, Gesine
van Rensburg, Craig
Larson, Bruce
Jamieson, Lise
Rosen, Sydney
Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title_full Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title_fullStr Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title_full_unstemmed Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title_short Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
title_sort revealed willingness-to-pay versus standard cost-effectiveness thresholds: evidence from the south african hiv investment case
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658054/
https://www.ncbi.nlm.nih.gov/pubmed/29073167
http://dx.doi.org/10.1371/journal.pone.0186496
work_keys_str_mv AT meyerrathgesine revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT vanrensburgcraig revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT larsonbruce revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT jamiesonlise revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT rosensydney revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase